

# Cipla posts profit, domestic biz clocks ₹1,044 cr revenue

PRESS TRUST OF INDIA

New Delhi

DRUG major Cipla on Wednesday posted a consolidated net profit of Rs 284.31 crore for the third quarter ended December 31, 2013. The company had posted a net profit of Rs 340.31 crore during the same period of the previous financial year.

Consolidated net sales of the company stood at Rs 2,552.63 crore for the third quarter. It stood at Rs 2,070.53 crore in the same period of previous financial year, Cipla said in a statement.

"Current year figures include the relevant results of Cipla's subsidiaries from the date they became subsidiary of the company and therefore the corresponding figures for the previous period are not comparable," the drugmaker added.

During the period under review, the company's domestic revenues stood at



## Good show

■ The company's exports of formulations stood at Rs 1,352 crore during the third quarter

■ Consolidated net sales of the company stood at Rs 2,552.63 crore for the third quarter

■ The firm announced the appointment of Peter Mugenyi as an independent director

Rs 1,044 crore. It stood at Rs 927 crore during the same period of previous financial year.

"The growth in domestic revenues was largely on account of growth in respiratory, anti-infectives and cardiology," the company said.

The company's exports of formulations stood at Rs 1,352 crore during the third quarter. It stood at Rs 1,006 crore during the same period of previous financial year.

"The growth in export revenues was primarily due to growth in anti-retroviral, anti-cancer, anti-allergic and anti-biotic segments," the firm added.

In a separate statement it announced the appointment of Peter Mugenyi as an independent director on the company's board with immediate effect.

Cipla's second quarter consolidated net profit fell 28.4 per cent YoY to Rs 358 crore, while total income from operations increased 14.6 per cent to Rs 2,512 crore.

CIPLA/BSE Rs 412.80 ▲

NSE Rs 412.75 ▲

Company